Abstract: The present invention relates to a powered toothbrush with two moving bristle bearing parts, the first such part is disc-shaped and rotates or oscillates back-and-forth, the second such part is coupled to the brush head by an elastomeric material, such that the second section can be moved either by the force of brushing or by selective engagement with the drive mechanism of the toothbrush.
Type:
Grant
Filed:
September 2, 2005
Date of Patent:
October 10, 2006
Assignee:
Colgate-Palmolive Company
Inventors:
Joseph Edward Fattori, John J. Gatzemeyer, Eyal Eliav
Abstract: An oral care composition having enhanced oral hygiene and antiplaque properties which comprises an orally acceptable vehicle containing a combination of an enzyme, cetylpyridinium chloride and a reducing agent.
Type:
Grant
Filed:
February 11, 2003
Date of Patent:
February 17, 2004
Assignee:
Colgate Palmolive Company
Inventors:
André M. Morgan, Lori H. Szeles, Malcolm Williams, Susan M. Herles, Chanda L. Macias, Robert D'Ambrogio, Thomas J. Boyd, James G. Masters
Abstract: The invention relates to compounds of formula (I):
wherein R1 and R10 are each independently of the other lower alkoxycarbonyl; either R2, R3 and R4 are each independently of the other C1-C4alkyl and R7, R8 and R9 are each selected from hydrogen and C1-C4alkyl, with not more than 2 of the radicals being hydrogen; or R7, R8 and R9 are each independently of the other C1-C4alkyl and R2, R3 and R4 are each selected from hydrogen and C1-C4alkyl, with 1 or 2 of the radicals being hydrogen; R5 is phenyl or cyclohexyl; and R6 is phenyl or cyanophenyl; or salts thereof; those compounds are inhibitors of retroviral aspartate proteases and are effective, for example, against HIV.
Type:
Grant
Filed:
May 21, 1998
Date of Patent:
May 1, 2001
Assignee:
Novartis AG
Inventors:
Alexander Fässler, Guido Bold, Hans-Georg Capraro, Marc Lang
Abstract: A method for the concomitant treatment of ischemia and arrhythmia in mammalian species which includes administering a combination of a potassium channel opener having little or no effect on action potential duration in the heart and a class III antiarrhythmic compound.
Abstract: In accordance with the present invention novel methods for cardiopulmonary bypass and organ transplant, each employing a potassium channel activator, are disclosed. The use of a potassium channel activator has been found to reduce the damage or ischemia induced by the bypass and transplant procedures.
Abstract: A method of preparing compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof which comprises converting a compound of the formula ##STR2## where the R.sup.2 substituent contains a hydrogen atom which is more acidic than the starred (*) hydrogen atom in formula II, to the corresponding dianion of formula ##STR3## where M is a counterion preferably lithium or magnesium, using two equivalents of a base in an inert solvent such as tetrahydrofuran; then reacting compounds of formula IIA with an epoxide of formula ##STR4## to produce the compounds of formula I.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
May 13, 1997
Assignee:
Bristol-Myers Squibb Company
Inventors:
David R. Kronenthal, Richard H. Mueller, Jollie D. Godfrey, Jr.
Abstract: Compounds of the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
Abstract: Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein a, b and d are all carbon atoms or one of a, b and d is a nitrogen atom or --N(O)-- and the others are carbon atoms; Y is a single bond, --CH.sub.2 --, --C(O)--, --O--, --S-- or --N(R.sup.8)--; and R.sup.1 to R.sup.7 are as defined herein. These compounds have potassium channel activating activity and are useful, therefore for example, as cardiovascular agents.
Abstract: Novel compounds are disclosed having the formula ##STR1## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. These compounds are useful, for example, as cardiovascular agents and especially as anti-ischemic agents.
Abstract: Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein X is a single bond, O, CO, S, NH or N(lower alkyl); Y is O, S or NCN; and R.sup.1 to R.sup.5' are as defined herein. These compounds have potassium channel activating activity and are useful, therefore for example, as cardiovascular agents.
Type:
Grant
Filed:
October 7, 1993
Date of Patent:
August 20, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Karnail S. Atwal, Francis N. Ferrara, Charles Z. Ding
Abstract: The invention relates to the use of an N-substituted heterocyclic derivative and its pharmaceutically acceptable salts for the treatment or prevention of cardiac arrhythmia.
Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sup.1 to R.sup.9 are as defined herein and m is the integer 0 or 1. These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity, gastrointestinal diseases and achalasia.
Type:
Grant
Filed:
December 2, 1994
Date of Patent:
July 30, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Philip M. Sher, William N. Washburn, Kathleen M. Poss
Abstract: A process for preparing compounds of the formula ##STR1## where a, b, c, R.sub.1, R.sub.2, and R.sub.3 are as defined herein including the step of alkylating a phenol of formula ##STR2## with an acetylene of formula ##STR3## where X is chlorine; bromine; --OC(O)--R.sub.5, where R.sub.5 is alkyl, aryl or substituted aryl; or --OCO.sub.2 R.sub.6, where R.sub.6 is alkyl or ##STR4## in the presence of a catalytic amount of a cuprous or cupric salt. The compounds of formula I are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
July 16, 1996
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Jollie D. Godfrey, Jr., Richard H. Mueller, Thomas C. Sedergran, Nachimuthu Soundararajan
Abstract: A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large intestine. The first component comprises the pharmacologically active substance, microcrystalline cellulose, a pH-sensitive polymer, and optionally an osmotic agent. The second component is a delayed release coating, and the third component is an enteric coating.
Type:
Grant
Filed:
June 24, 1994
Date of Patent:
July 16, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert Abramowitz, Sunanda A. Ranadive, Sailesh A. Varia, Nemichand B. Jain
Abstract: Novel compounds having potassium channel activating activity and useful, for example, as antiischemic agents are disclosed. These compounds have the general formula ##STR1## wherein A is ##STR2## or a single bond to complete an indoline nucleus; X is --O--, --S-- or --NCN; and the R groups are as defined herein.
Abstract: A process for preparing compounds of the formula ##STR1## where a, b d, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein including condensation of a phenol of formula ##STR2## with an acetal of formula ##STR3## in the presence of a catalytic amount of a tertiary amine. The compounds of formula I are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.
Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: A is a bond or --OCH.sub.2 --, where the oxygen is linked to R.sup.1 ;B is --CH.sub.2 -- or when R.sup.3 is hydrogen, B may be --CH.sub.2 O-- where the oxygen is linked to the phenyl ring;R.sup.1 is an aryl group;R.sup.2 is hydrogen or lower alkyl;R.sup.3 is hydrogen; or R.sup.2 and R.sup.3 together form the group --CH.sub.2 CH.sub.2 --; andR.sup.4 is --SO.sub.3 H, --P(O.sub.2 H)R.sup.5, --P(O.sub.2 R.sup.5')R.sup.5, --PO.sub.3 H.sub.2, --PO.sub.3 HR.sup.5' or --PO.sub.3 (R.sup.5').sub.2 where R.sup.5 and R.sup.5' are independently lower alkyl. These compounds are beta.sub.3 adrenergic receptor agonists and are useful, for example, in the treatment of diabetes, obesity, achalasia, and gastrointestinal diseases.
Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof where A is phenyl, naphthyl or dihydro- or tetrahydronaphthyl optionally substituted on the aromatic ring by one to three substituents independently selected from halogen, cyano, trifluoromethyl, nitro, alkoxy, alkylsulfonyl, alkyl, cycloalkyl, aryl or a hydrogen bond donor; B is a bond or an oxygen atom and R.sup.1 to R.sup.4 are as defined herein. These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.